Through a comprehensive series of in vitro, in vivo, and patient-derived organoid experiments, we identified STK38 as a critical modulator of tumor heterogeneity and demonstrated the therapeutic value of targeting its downstream effectors in STK38-high pRCC tumors. This evidence concerns the gene STK38 and neoplasm.